CA2997912A1 - Genetic engineering of macrophages for immunotherapy - Google Patents
Genetic engineering of macrophages for immunotherapy Download PDFInfo
- Publication number
- CA2997912A1 CA2997912A1 CA2997912A CA2997912A CA2997912A1 CA 2997912 A1 CA2997912 A1 CA 2997912A1 CA 2997912 A CA2997912 A CA 2997912A CA 2997912 A CA2997912 A CA 2997912A CA 2997912 A1 CA2997912 A1 CA 2997912A1
- Authority
- CA
- Canada
- Prior art keywords
- alternatives
- cell
- protein
- genetically modified
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002540 macrophage Anatomy 0.000 title claims description 83
- 238000009169 immunotherapy Methods 0.000 title description 12
- 238000010353 genetic engineering Methods 0.000 title description 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 381
- 210000002865 immune cell Anatomy 0.000 claims abstract description 258
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 229
- 210000004027 cell Anatomy 0.000 claims abstract description 221
- 239000013598 vector Substances 0.000 claims abstract description 216
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 172
- 238000000034 method Methods 0.000 claims abstract description 142
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 94
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 87
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 87
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 87
- 210000000822 natural killer cell Anatomy 0.000 claims abstract description 69
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 57
- 102000019034 Chemokines Human genes 0.000 claims abstract description 53
- 108010012236 Chemokines Proteins 0.000 claims abstract description 53
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 50
- 108091008324 binding proteins Proteins 0.000 claims abstract description 50
- 102000004127 Cytokines Human genes 0.000 claims abstract description 38
- 108090000695 Cytokines Proteins 0.000 claims abstract description 38
- 238000004519 manufacturing process Methods 0.000 claims abstract description 33
- 102000014150 Interferons Human genes 0.000 claims abstract description 30
- 108010050904 Interferons Proteins 0.000 claims abstract description 30
- 230000004913 activation Effects 0.000 claims abstract description 30
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 29
- 230000006052 T cell proliferation Effects 0.000 claims abstract description 27
- 229940079322 interferon Drugs 0.000 claims abstract description 26
- 102000015696 Interleukins Human genes 0.000 claims abstract description 25
- 108010063738 Interleukins Proteins 0.000 claims abstract description 25
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 claims abstract description 24
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 claims abstract description 24
- 230000002688 persistence Effects 0.000 claims abstract description 24
- 230000028993 immune response Effects 0.000 claims abstract description 17
- 238000011319 anticancer therapy Methods 0.000 claims abstract description 15
- 230000035755 proliferation Effects 0.000 claims abstract description 14
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 claims abstract description 13
- 108700010013 HMGB1 Proteins 0.000 claims abstract description 13
- 101150021904 HMGB1 gene Proteins 0.000 claims abstract description 13
- 102100037907 High mobility group protein B1 Human genes 0.000 claims abstract description 13
- 230000002924 anti-infective effect Effects 0.000 claims abstract description 13
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 13
- 230000001629 suppression Effects 0.000 claims abstract description 11
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 7
- 230000001965 increasing effect Effects 0.000 claims abstract description 5
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 121
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 115
- 108091033409 CRISPR Proteins 0.000 claims description 101
- 230000027455 binding Effects 0.000 claims description 88
- 210000001616 monocyte Anatomy 0.000 claims description 67
- 239000012634 fragment Substances 0.000 claims description 64
- -1 CCL22 Proteins 0.000 claims description 60
- 230000014509 gene expression Effects 0.000 claims description 58
- 210000000066 myeloid cell Anatomy 0.000 claims description 58
- 102000006992 Interferon-alpha Human genes 0.000 claims description 56
- 108010047761 Interferon-alpha Proteins 0.000 claims description 56
- 230000001939 inductive effect Effects 0.000 claims description 54
- 230000001105 regulatory effect Effects 0.000 claims description 51
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 48
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 48
- 108090000467 Interferon-beta Proteins 0.000 claims description 47
- 102000003996 Interferon-beta Human genes 0.000 claims description 47
- 229960001388 interferon-beta Drugs 0.000 claims description 46
- 238000010354 CRISPR gene editing Methods 0.000 claims description 43
- 108010074328 Interferon-gamma Proteins 0.000 claims description 42
- 102000008070 Interferon-gamma Human genes 0.000 claims description 41
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 41
- 239000003814 drug Substances 0.000 claims description 41
- 108020005004 Guide RNA Proteins 0.000 claims description 40
- 229960003130 interferon gamma Drugs 0.000 claims description 40
- 230000004927 fusion Effects 0.000 claims description 39
- 201000011510 cancer Diseases 0.000 claims description 38
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 36
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 34
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 34
- 108020004999 messenger RNA Proteins 0.000 claims description 33
- 102000013462 Interleukin-12 Human genes 0.000 claims description 32
- 108010065805 Interleukin-12 Proteins 0.000 claims description 32
- 229940002612 prodrug Drugs 0.000 claims description 31
- 239000000651 prodrug Substances 0.000 claims description 31
- 108090000172 Interleukin-15 Proteins 0.000 claims description 29
- 102000003812 Interleukin-15 Human genes 0.000 claims description 29
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 29
- 108020004705 Codon Proteins 0.000 claims description 28
- 102000003814 Interleukin-10 Human genes 0.000 claims description 27
- 108090000174 Interleukin-10 Proteins 0.000 claims description 27
- 102000003810 Interleukin-18 Human genes 0.000 claims description 27
- 108090000171 Interleukin-18 Proteins 0.000 claims description 27
- 208000005017 glioblastoma Diseases 0.000 claims description 27
- 230000000770 proinflammatory effect Effects 0.000 claims description 27
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 26
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 26
- 102100023688 Eotaxin Human genes 0.000 claims description 26
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 26
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 26
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 26
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 26
- 229960002963 ganciclovir Drugs 0.000 claims description 26
- 241000700605 Viruses Species 0.000 claims description 25
- 239000000556 agonist Substances 0.000 claims description 25
- 239000003112 inhibitor Substances 0.000 claims description 25
- 210000004881 tumor cell Anatomy 0.000 claims description 25
- 102100023702 C-C motif chemokine 13 Human genes 0.000 claims description 24
- 102100034871 C-C motif chemokine 8 Human genes 0.000 claims description 24
- 102100036153 C-X-C motif chemokine 6 Human genes 0.000 claims description 24
- 108090001005 Interleukin-6 Proteins 0.000 claims description 24
- 102000004889 Interleukin-6 Human genes 0.000 claims description 24
- 102100035304 Lymphotactin Human genes 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 24
- 230000001225 therapeutic effect Effects 0.000 claims description 24
- 102100023705 C-C motif chemokine 14 Human genes 0.000 claims description 23
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims description 23
- 101000978381 Homo sapiens C-C motif chemokine 14 Proteins 0.000 claims description 23
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 claims description 23
- 102100036154 Platelet basic protein Human genes 0.000 claims description 23
- 102100030704 Interleukin-21 Human genes 0.000 claims description 22
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 22
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 22
- 108010074108 interleukin-21 Proteins 0.000 claims description 22
- 239000013603 viral vector Substances 0.000 claims description 22
- 208000015181 infectious disease Diseases 0.000 claims description 21
- 210000005260 human cell Anatomy 0.000 claims description 20
- 229960001603 tamoxifen Drugs 0.000 claims description 20
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 19
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 19
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 19
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 19
- 150000001413 amino acids Chemical class 0.000 claims description 18
- 238000012258 culturing Methods 0.000 claims description 18
- 102000004452 Arginase Human genes 0.000 claims description 17
- 108700024123 Arginases Proteins 0.000 claims description 17
- 108090000978 Interleukin-4 Proteins 0.000 claims description 17
- 108010002586 Interleukin-7 Proteins 0.000 claims description 17
- 102100021592 Interleukin-7 Human genes 0.000 claims description 17
- 238000013518 transcription Methods 0.000 claims description 17
- 230000035897 transcription Effects 0.000 claims description 17
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 16
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 15
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims description 15
- 102000000589 Interleukin-1 Human genes 0.000 claims description 15
- 108010002352 Interleukin-1 Proteins 0.000 claims description 15
- 108091008874 T cell receptors Proteins 0.000 claims description 15
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 15
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 15
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 15
- 230000000735 allogeneic effect Effects 0.000 claims description 15
- 210000004981 tumor-associated macrophage Anatomy 0.000 claims description 15
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 14
- 102100021935 C-C motif chemokine 26 Human genes 0.000 claims description 14
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims description 14
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 claims description 14
- 108010002350 Interleukin-2 Proteins 0.000 claims description 14
- 102000000588 Interleukin-2 Human genes 0.000 claims description 14
- 108010065637 Interleukin-23 Proteins 0.000 claims description 14
- 102000013264 Interleukin-23 Human genes 0.000 claims description 14
- 239000002207 metabolite Substances 0.000 claims description 14
- 238000013519 translation Methods 0.000 claims description 14
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 13
- 102100036849 C-C motif chemokine 24 Human genes 0.000 claims description 13
- 102100032366 C-C motif chemokine 7 Human genes 0.000 claims description 13
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 claims description 13
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 claims description 13
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims description 13
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 13
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 13
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 claims description 13
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 108020001507 fusion proteins Proteins 0.000 claims description 13
- 102000037865 fusion proteins Human genes 0.000 claims description 13
- 239000003446 ligand Substances 0.000 claims description 13
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 13
- 150000003384 small molecules Chemical class 0.000 claims description 13
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims description 12
- 101710112613 C-C motif chemokine 13 Proteins 0.000 claims description 12
- 102100036842 C-C motif chemokine 19 Human genes 0.000 claims description 12
- 102100021936 C-C motif chemokine 27 Human genes 0.000 claims description 12
- 101710155833 C-C motif chemokine 8 Proteins 0.000 claims description 12
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims description 12
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 claims description 12
- 101710139422 Eotaxin Proteins 0.000 claims description 12
- 101000978379 Homo sapiens C-C motif chemokine 13 Proteins 0.000 claims description 12
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims description 12
- 101000713078 Homo sapiens C-C motif chemokine 24 Proteins 0.000 claims description 12
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 claims description 12
- 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 claims description 12
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 claims description 12
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 claims description 12
- 101000947177 Homo sapiens C-X-C motif chemokine 6 Proteins 0.000 claims description 12
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 claims description 12
- 101000973997 Homo sapiens Nucleosome assembly protein 1-like 4 Proteins 0.000 claims description 12
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 claims description 12
- 108700012411 TNFSF10 Proteins 0.000 claims description 12
- 108010019677 lymphotactin Proteins 0.000 claims description 12
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 claims description 12
- 102100036850 C-C motif chemokine 23 Human genes 0.000 claims description 11
- 101710085504 C-X-C motif chemokine 6 Proteins 0.000 claims description 11
- 101150021185 FGF gene Proteins 0.000 claims description 11
- 101710115997 Gamma-tubulin complex component 2 Proteins 0.000 claims description 11
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 claims description 11
- 101000897494 Homo sapiens C-C motif chemokine 27 Proteins 0.000 claims description 11
- 101100222381 Homo sapiens CXCL11 gene Proteins 0.000 claims description 11
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 claims description 11
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims description 11
- 102100026236 Interleukin-8 Human genes 0.000 claims description 11
- 101100222387 Mus musculus Cxcl15 gene Proteins 0.000 claims description 11
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 11
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 11
- 108020004440 Thymidine kinase Proteins 0.000 claims description 11
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 claims description 11
- 102000015694 estrogen receptors Human genes 0.000 claims description 11
- 108010038795 estrogen receptors Proteins 0.000 claims description 11
- 230000002025 microglial effect Effects 0.000 claims description 11
- 238000012384 transportation and delivery Methods 0.000 claims description 11
- 102000011727 Caspases Human genes 0.000 claims description 10
- 108010076667 Caspases Proteins 0.000 claims description 10
- 241000700584 Simplexvirus Species 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 10
- 238000002659 cell therapy Methods 0.000 claims description 10
- 150000003431 steroids Chemical class 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 9
- 208000026310 Breast neoplasm Diseases 0.000 claims description 9
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 9
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 9
- 229940082789 erbitux Drugs 0.000 claims description 9
- 208000020816 lung neoplasm Diseases 0.000 claims description 9
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 9
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 8
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims description 8
- 206010029260 Neuroblastoma Diseases 0.000 claims description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 claims description 8
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 claims description 8
- 206010038389 Renal cancer Diseases 0.000 claims description 8
- 206010039491 Sarcoma Diseases 0.000 claims description 8
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 8
- 208000000277 Splenic Neoplasms Diseases 0.000 claims description 8
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 8
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 8
- 102100026497 Zinc finger protein 654 Human genes 0.000 claims description 8
- 230000000903 blocking effect Effects 0.000 claims description 8
- 208000029742 colonic neoplasm Diseases 0.000 claims description 8
- 206010017758 gastric cancer Diseases 0.000 claims description 8
- 229940088597 hormone Drugs 0.000 claims description 8
- 239000005556 hormone Substances 0.000 claims description 8
- 201000010982 kidney cancer Diseases 0.000 claims description 8
- 229940043355 kinase inhibitor Drugs 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 208000014018 liver neoplasm Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 8
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 8
- 201000002528 pancreatic cancer Diseases 0.000 claims description 8
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 8
- 201000000849 skin cancer Diseases 0.000 claims description 8
- 201000002471 spleen cancer Diseases 0.000 claims description 8
- 201000011549 stomach cancer Diseases 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 206010046766 uterine cancer Diseases 0.000 claims description 8
- 206010018338 Glioma Diseases 0.000 claims description 7
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 claims description 7
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 claims description 7
- 238000002512 chemotherapy Methods 0.000 claims description 7
- 229940022353 herceptin Drugs 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 230000005855 radiation Effects 0.000 claims description 7
- 238000012546 transfer Methods 0.000 claims description 7
- 208000032612 Glial tumor Diseases 0.000 claims description 6
- 229940126573 antibacterial therapeutic Drugs 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 230000002159 abnormal effect Effects 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 4
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 4
- 238000011357 CAR T-cell therapy Methods 0.000 claims description 4
- 108010065524 CD52 Antigen Proteins 0.000 claims description 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 4
- 101150029707 ERBB2 gene Proteins 0.000 claims description 4
- 241000991587 Enterovirus C Species 0.000 claims description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 4
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 4
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 4
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims description 4
- 102100034256 Mucin-1 Human genes 0.000 claims description 4
- 108010008707 Mucin-1 Proteins 0.000 claims description 4
- 102100023123 Mucin-16 Human genes 0.000 claims description 4
- 102000003425 Tyrosinase Human genes 0.000 claims description 4
- 108060008724 Tyrosinase Proteins 0.000 claims description 4
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 4
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 4
- 229960002932 anastrozole Drugs 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 238000006471 dimerization reaction Methods 0.000 claims description 4
- 239000000411 inducer Substances 0.000 claims description 4
- 229960003881 letrozole Drugs 0.000 claims description 4
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 4
- 230000000174 oncolytic effect Effects 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 230000035939 shock Effects 0.000 claims description 4
- 239000000878 small molecule-drug conjugate Substances 0.000 claims description 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 4
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 4
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 14
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 2
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims 2
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 claims 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 claims 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 203
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 24
- 241000713666 Lentivirus Species 0.000 description 21
- 239000002158 endotoxin Substances 0.000 description 20
- 229920006008 lipopolysaccharide Polymers 0.000 description 20
- 230000006870 function Effects 0.000 description 16
- 230000004069 differentiation Effects 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 102000001301 EGF receptor Human genes 0.000 description 14
- 108060006698 EGF receptor Proteins 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 14
- 230000000670 limiting effect Effects 0.000 description 14
- 102000053602 DNA Human genes 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 229920002477 rna polymer Polymers 0.000 description 13
- 230000014616 translation Effects 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 12
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 12
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 12
- 238000000684 flow cytometry Methods 0.000 description 12
- 238000011282 treatment Methods 0.000 description 11
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 10
- 210000000987 immune system Anatomy 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 9
- 231100000433 cytotoxic Toxicity 0.000 description 8
- 230000001472 cytotoxic effect Effects 0.000 description 8
- 230000001506 immunosuppresive effect Effects 0.000 description 8
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000004614 tumor growth Effects 0.000 description 8
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 238000002648 combination therapy Methods 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 238000010188 recombinant method Methods 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 238000010361 transduction Methods 0.000 description 7
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 238000010362 genome editing Methods 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 230000026683 transduction Effects 0.000 description 6
- 238000011870 unpaired t-test Methods 0.000 description 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 101710149136 Protein Vpr Proteins 0.000 description 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 5
- 239000003636 conditioned culture medium Substances 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 239000013607 AAV vector Substances 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 description 4
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 4
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 4
- 238000010459 TALEN Methods 0.000 description 4
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000003750 conditioning effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 230000037451 immune surveillance Effects 0.000 description 4
- 239000002955 immunomodulating agent Substances 0.000 description 4
- 229940121354 immunomodulator Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229940047124 interferons Drugs 0.000 description 4
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108091006106 transcriptional activators Proteins 0.000 description 4
- 102100027211 Albumin Human genes 0.000 description 3
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 3
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 3
- 238000010453 CRISPR/Cas method Methods 0.000 description 3
- 102100031780 Endonuclease Human genes 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 108010067003 Interleukin-33 Proteins 0.000 description 3
- 102000017761 Interleukin-33 Human genes 0.000 description 3
- 108010038498 Interleukin-7 Receptors Proteins 0.000 description 3
- 102000010782 Interleukin-7 Receptors Human genes 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 239000012270 PD-1 inhibitor Substances 0.000 description 3
- 239000012668 PD-1-inhibitor Substances 0.000 description 3
- 108090000829 Ribosome Inactivating Proteins Proteins 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000006023 anti-tumor response Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000001461 cytolytic effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000001024 immunotherapeutic effect Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 238000011201 multiple comparisons test Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229940121655 pd-1 inhibitor Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000016914 ras Proteins Human genes 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- MHJBZVSGOZTKRH-IZHYLOQSSA-N 4-Hydroxy-N-desmethyltamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCNC)=CC=1)/C1=CC=C(O)C=C1 MHJBZVSGOZTKRH-IZHYLOQSSA-N 0.000 description 2
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 2
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 2
- 102100034289 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 108700019718 SAM Domain and HD Domain-Containing Protein 1 Proteins 0.000 description 2
- 101150114242 SAMHD1 gene Proteins 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 102100035100 Transcription factor p65 Human genes 0.000 description 2
- 108010052104 Viral Regulatory and Accessory Proteins Proteins 0.000 description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- TXUZVZSFRXZGTL-QPLCGJKRSA-N afimoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=C(O)C=C1 TXUZVZSFRXZGTL-QPLCGJKRSA-N 0.000 description 2
- 229950003105 afimoxifene Drugs 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 125000000837 carbohydrate group Chemical group 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 108700010039 chimeric receptor Proteins 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 206010052015 cytokine release syndrome Diseases 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 230000008629 immune suppression Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 229950000038 interferon alfa Drugs 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 238000010234 longitudinal analysis Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 210000000274 microglia Anatomy 0.000 description 2
- 210000000581 natural killer T-cell Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 102220101652 rs878854761 Human genes 0.000 description 2
- 108091006024 signal transducing proteins Proteins 0.000 description 2
- 102000034285 signal transducing proteins Human genes 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 102100024365 Arf-GAP domain and FG repeat-containing protein 1 Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- PCLCDPVEEFVAAQ-UHFFFAOYSA-N BCA 1 Chemical compound CC(CO)CCCC(C)C1=CCC(C)(O)C1CC2=C(O)C(O)CCC2=O PCLCDPVEEFVAAQ-UHFFFAOYSA-N 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 102100023703 C-C motif chemokine 15 Human genes 0.000 description 1
- 102100023698 C-C motif chemokine 17 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100036845 C-C motif chemokine 22 Human genes 0.000 description 1
- 101710112538 C-C motif chemokine 27 Proteins 0.000 description 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 1
- 102400000583 C80 Human genes 0.000 description 1
- 101800001507 C80 Proteins 0.000 description 1
- 238000011523 CAR-T cell immunotherapy Methods 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 101150093802 CXCL1 gene Proteins 0.000 description 1
- 101100450705 Caenorhabditis elegans hif-1 gene Proteins 0.000 description 1
- 101100028791 Caenorhabditis elegans pbs-5 gene Proteins 0.000 description 1
- 108010083647 Chemokine CCL24 Proteins 0.000 description 1
- 108010083698 Chemokine CCL26 Proteins 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102100040606 Dermatan-sulfate epimerase Human genes 0.000 description 1
- 101710121366 Disintegrin and metalloproteinase domain-containing protein 11 Proteins 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000014061 Extranodal Extension Diseases 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 102000013818 Fractalkine Human genes 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 101000978376 Homo sapiens C-C motif chemokine 15 Proteins 0.000 description 1
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101100441523 Homo sapiens CXCL5 gene Proteins 0.000 description 1
- 101000816698 Homo sapiens Dermatan-sulfate epimerase Proteins 0.000 description 1
- 101000856606 Homo sapiens GTP-binding protein GEM Proteins 0.000 description 1
- 101001058904 Homo sapiens Gamma-tubulin complex component 2 Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101001014636 Homo sapiens Golgin subfamily A member 4 Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101001002470 Homo sapiens Interferon lambda-1 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102100020990 Interferon lambda-1 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 101800003050 Interleukin-16 Proteins 0.000 description 1
- 102000049772 Interleukin-16 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- 101710177504 Kit ligand Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 101710164418 Movement protein TGB2 Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102100022396 Nucleosome assembly protein 1-like 4 Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- ZJPGOXWRFNKIQL-JYJNAYRXSA-N Phe-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 ZJPGOXWRFNKIQL-JYJNAYRXSA-N 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710149109 Protein Vpx Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102100029618 Rab-like protein 6 Human genes 0.000 description 1
- 101150076252 Rabl6 gene Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100021225 Serine hydroxymethyltransferase, cytosolic Human genes 0.000 description 1
- 108700025832 Serum Response Element Proteins 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 240000003243 Thuja occidentalis Species 0.000 description 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
- 102100027188 Thyroid peroxidase Human genes 0.000 description 1
- 101710113649 Thyroid peroxidase Proteins 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 101710165741 Virion-associated protein Proteins 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine group Chemical group [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 201000002797 childhood leukemia Diseases 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 229940124447 delivery agent Drugs 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000012938 design process Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- PGUYAANYCROBRT-UHFFFAOYSA-N dihydroxy-selanyl-selanylidene-lambda5-phosphane Chemical compound OP(O)([SeH])=[Se] PGUYAANYCROBRT-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000053685 human GEM Human genes 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 230000005746 immune checkpoint blockade Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 230000007944 immunity cancer cycle Effects 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 108090000681 interleukin 20 Proteins 0.000 description 1
- 102000004114 interleukin 20 Human genes 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 230000006724 microglial activation Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000012223 nuclear import Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000030266 primary brain neoplasm Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000002473 ribonucleic acid immunoprecipitation Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- JRPHGDYSKGJTKZ-UHFFFAOYSA-K selenophosphate Chemical compound [O-]P([O-])([O-])=[Se] JRPHGDYSKGJTKZ-UHFFFAOYSA-K 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/17—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Developmental Biology & Embryology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562216224P | 2015-09-09 | 2015-09-09 | |
| US62/216,224 | 2015-09-09 | ||
| US201662361348P | 2016-07-12 | 2016-07-12 | |
| US62/361,348 | 2016-07-12 | ||
| PCT/US2016/050552 WO2017044487A1 (en) | 2015-09-09 | 2016-09-07 | Genetic engineering of macrophages for immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2997912A1 true CA2997912A1 (en) | 2017-03-16 |
Family
ID=58240865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2997912A Pending CA2997912A1 (en) | 2015-09-09 | 2016-09-07 | Genetic engineering of macrophages for immunotherapy |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10525082B2 (enExample) |
| EP (1) | EP3347026A4 (enExample) |
| JP (3) | JP6959909B2 (enExample) |
| CN (1) | CN108243607A (enExample) |
| AU (1) | AU2016318773B2 (enExample) |
| CA (1) | CA2997912A1 (enExample) |
| HK (1) | HK1257460A1 (enExample) |
| SG (1) | SG10201913151TA (enExample) |
| WO (1) | WO2017044487A1 (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150320799A1 (en) | 2012-12-20 | 2015-11-12 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| GB201418965D0 (enExample) | 2014-10-24 | 2014-12-10 | Ospedale San Raffaele And Fond Telethon | |
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| AU2016318773B2 (en) | 2015-09-09 | 2024-08-01 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Genetic engineering of macrophages for immunotherapy |
| WO2017136322A1 (en) | 2016-02-04 | 2017-08-10 | Zhenglun Zhu | Treatment and diagnosis of inflammatory disorders |
| CN117143837A (zh) | 2016-03-25 | 2023-12-01 | 普瑞菲根公司 | 高转导hsv载体 |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| CA3058434A1 (en) * | 2017-03-28 | 2018-10-04 | Zhenglun Zhu | Methods of treating neoplastic diseases |
| SG10202111394XA (en) * | 2017-04-13 | 2021-12-30 | Senti Biosciences Inc | Combinatorial cancer immunotherapy |
| WO2018213332A1 (en) * | 2017-05-17 | 2018-11-22 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Generating mammalian t cell activation inducible synthetic promoters (syn+pro) to improve t cell therapy |
| US11168326B2 (en) | 2017-07-11 | 2021-11-09 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| US20230061455A1 (en) * | 2017-11-01 | 2023-03-02 | Editas Medicine, Inc. | Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy |
| AU2018370217A1 (en) * | 2017-11-17 | 2020-05-28 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for alleviating Cytokine Release Syndrome |
| AU2019209432A1 (en) | 2018-01-22 | 2020-08-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for CAR T cells |
| WO2019165237A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| US11267866B2 (en) | 2018-04-04 | 2022-03-08 | Nant Holdings Ip, Llc | Immunoglobulin complex comprising interleukin-15 |
| WO2019200325A1 (en) * | 2018-04-12 | 2019-10-17 | Kite Pharma, Inc. | Chimeric receptor t cell treatment using characteristics of the tumor microenvironment |
| CN108727504B (zh) * | 2018-04-16 | 2021-08-27 | 泉州向日葵生物科技有限公司 | 一种ifn与抗pd-l1抗体的融合蛋白及其应用 |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| CN112334577B (zh) | 2018-04-19 | 2023-10-17 | 加利福尼亚大学董事会 | 用于基因编辑的组合物和方法 |
| WO2019217327A1 (en) * | 2018-05-07 | 2019-11-14 | Bellicum Pharmaceuticals, Inc. | Natural killer cell products and methods |
| WO2019222423A1 (en) * | 2018-05-15 | 2019-11-21 | The Brigham And Women's Hospital, Inc. | Compositions and methods related to tumor cell killers and vaccines |
| WO2019246261A1 (en) * | 2018-06-19 | 2019-12-26 | Regents Of The University Of Minnesota | Genome engineering primary monocytes |
| CN118147029A (zh) | 2018-07-11 | 2024-06-07 | 阿克蒂姆治疗有限公司 | 工程化的免疫刺激性细菌菌株及其用途 |
| CN108823171A (zh) * | 2018-07-24 | 2018-11-16 | 武汉赛云博生物科技有限公司 | 一种基因工程细胞及体外高效扩增nk细胞的方法 |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| GB201818110D0 (en) * | 2018-11-06 | 2018-12-19 | Macrophox Ltd | Monocytes for cancer targeting |
| EP3876977A1 (en) | 2018-11-06 | 2021-09-15 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
| US20220000921A1 (en) * | 2018-11-20 | 2022-01-06 | Innovative Cellular Therapeutics Holdings, Ltd. | Modified Cell Expressing Therapeutic Agent and Uses thereof |
| EP3912629A4 (en) * | 2018-12-17 | 2022-10-12 | Cure Genetics Co., Ltd | Method for delivering gene in cells |
| WO2020160217A1 (en) * | 2019-02-01 | 2020-08-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Microenvironment sensors to regulate engineered gene expression |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| CA3176660A1 (en) * | 2019-02-27 | 2020-09-03 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| JP2022531814A (ja) * | 2019-03-12 | 2022-07-12 | イノベイティブ セルラー セラピューティクス ホールディングス，エルティディ | 改変細胞の増幅およびその応用 |
| US20220184091A1 (en) * | 2019-03-28 | 2022-06-16 | Sierra Oncology, Inc. | Methods of Treating Cancer with Chk1 Inhibitors |
| US11013764B2 (en) | 2019-04-30 | 2021-05-25 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
| CN110760480B (zh) * | 2019-07-09 | 2021-07-02 | 杭州师范大学 | 一种抗肿瘤nk细胞及其制备方法 |
| KR20220097875A (ko) | 2019-09-03 | 2022-07-08 | 마이얼로이드 테라퓨틱스, 인크. | 게놈 통합을 위한 방법 및 조성물 |
| JP2022548069A (ja) * | 2019-09-11 | 2022-11-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | キメラ直交受容体タンパク質および使用方法 |
| JP7749543B2 (ja) * | 2019-09-17 | 2025-10-06 | オハイオ・ステイト・イノベーション・ファウンデーション | ヒト抗ｐｄ－ｌ１ペプチドワクチン及びその使用方法 |
| WO2021064655A1 (en) * | 2019-10-02 | 2021-04-08 | Massachusetts Institute Of Technology | High-throughput genetic screening |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| CN111150748A (zh) * | 2019-12-27 | 2020-05-15 | 杭州荣谷生物科技有限公司 | 重组溶瘤病毒在制备治疗消化道癌药物中的用途 |
| CN111087460B (zh) * | 2020-01-14 | 2021-07-30 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 一种广谱型抗菌肽及其应用 |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| IL296511A (en) | 2020-03-20 | 2022-11-01 | Lyell Immunopharma Inc | Novel recombinant cell surface markers |
| GB202007906D0 (en) | 2020-05-27 | 2020-07-08 | Univ Edinburgh | Method of transfecting macrophages |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| EP4161536A4 (en) | 2020-06-04 | 2024-08-14 | Carisma Therapeutics Inc. | Novel constructs for chimeric antigen receptors |
| MX2023005201A (es) | 2020-11-04 | 2023-06-28 | Myeloid Therapeutics Inc | Composiciones de proteinas de fusion quimerica modificadas por ingenieria y metodos de uso de las mismas. |
| WO2022165260A1 (en) * | 2021-01-29 | 2022-08-04 | Iovance Biotherapeutics, Inc. | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| BR112023018832A2 (pt) | 2021-03-17 | 2023-12-26 | Myeloid Therapeutics Inc | Composições de proteínas de fusão quiméricas modificadas e métodos de uso das mesmas |
| EP4337268A4 (en) | 2021-05-11 | 2025-06-04 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| AU2022307402A1 (en) * | 2021-07-09 | 2024-01-25 | Legend Biotech Ireland Limited | Mutant il-15 compositions and methods thereof |
| WO2023053828A1 (ja) * | 2021-09-30 | 2023-04-06 | テルモ株式会社 | 化学療法制御装置、化学療法制御システム、化学療法制御装置の制御方法及び化学療法制御プログラム |
| WO2023076348A1 (en) * | 2021-10-27 | 2023-05-04 | The Regents Of The University Of California | Combination of human natural killer cells and macrophages for cancer therapy |
| CN114404600B (zh) * | 2022-01-21 | 2023-06-27 | 首都医科大学附属北京同仁医院 | 一种用于治疗肿瘤的药物组合及其应用 |
| CN114657143B (zh) * | 2022-03-11 | 2022-10-25 | 西安电子科技大学 | 一种肿瘤微环境调控型car-单核/巨噬细胞及其制备方法和应用 |
| KR20250006903A (ko) * | 2022-04-18 | 2025-01-13 | 칸델 쎄라퓨틱스, 인크. | 바이러스 벡터를 위한 조성물 및 방법 |
| WO2023205657A2 (en) * | 2022-04-18 | 2023-10-26 | City Of Hope | Compositions for restoring mecp2 gene function and methods of use thereof |
| WO2024215990A2 (en) * | 2023-04-13 | 2024-10-17 | William Marsh Rice University | Regulated cells expressing cytokines |
| CN119020422A (zh) * | 2024-10-28 | 2024-11-26 | 昆明医科大学 | 一种稳转萤火虫萤光素酶靶细胞株的构建方法及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2286819A1 (en) | 1997-04-17 | 1998-10-22 | Flossie Wong-Staal | Use of lentiviral vectors for antigen presentation in dendritic cells |
| US7432351B1 (en) * | 2002-10-04 | 2008-10-07 | Mayo Foundation For Medical Education And Research | B7-H1 variants |
| AU2006304392B2 (en) * | 2005-10-18 | 2014-05-01 | National Jewish Health | Conditionally immortalized long-term stem cells and methods of making and using such cells |
| US7919079B2 (en) * | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
| US9023648B2 (en) * | 2009-12-30 | 2015-05-05 | University Of Massachusetts | Method of transducing non-dividing myeloid cells utilizing chimeric murine leukemia viruses containing Vpx |
| CA2794483C (en) * | 2010-03-26 | 2020-07-07 | Trustees Of Dartmouth College | Vista regulatory t cell mediator protein, vista binding agents and use thereof |
| KR101976882B1 (ko) | 2011-03-23 | 2019-05-09 | 프레드 헛친슨 켄서 리서치 센터 | 세포 면역요법용 방법 및 조성물 |
| US20140255363A1 (en) | 2011-09-16 | 2014-09-11 | Baylor College Of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| JP6850528B2 (ja) * | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| US8323662B1 (en) * | 2012-03-30 | 2012-12-04 | Immune Design Corp. | Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein |
| US9713635B2 (en) * | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
| PL2884999T3 (pl) | 2012-08-20 | 2021-07-05 | Fred Hutchinson Cancer Research Center | Sposób i kompozycje do immunoterapii komórkowej |
| ES2824024T3 (es) * | 2012-10-10 | 2021-05-11 | Sangamo Therapeutics Inc | Compuestos modificadores de células T y usos de los mismos |
| US20160015750A1 (en) * | 2013-03-09 | 2016-01-21 | Baylor College Of Medicine | Vascular-targeted t-cell therapy |
| US9587032B2 (en) * | 2013-06-12 | 2017-03-07 | The Board Of Trustees Of The Leland Stanford Junior University | IgE antibodies for the inhibition of tumor metastasis |
| ES2792849T3 (es) * | 2014-02-10 | 2020-11-12 | Univ Emory | Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer |
| KR102697827B1 (ko) * | 2015-07-28 | 2024-08-23 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 키메릭 항원 수용체를 발현하는 변형된 단핵세포/대식세포 및 그의 용도 |
| US11352439B2 (en) | 2015-08-13 | 2022-06-07 | Kim Leslie O'Neill | Macrophage CAR (MOTO-CAR) in immunotherapy |
| AU2016318773B2 (en) | 2015-09-09 | 2024-08-01 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Genetic engineering of macrophages for immunotherapy |
-
2016
- 2016-09-07 AU AU2016318773A patent/AU2016318773B2/en active Active
- 2016-09-07 CN CN201680065510.4A patent/CN108243607A/zh active Pending
- 2016-09-07 HK HK18116695.4A patent/HK1257460A1/zh unknown
- 2016-09-07 US US15/258,887 patent/US10525082B2/en active Active
- 2016-09-07 EP EP16844978.3A patent/EP3347026A4/en active Pending
- 2016-09-07 CA CA2997912A patent/CA2997912A1/en active Pending
- 2016-09-07 WO PCT/US2016/050552 patent/WO2017044487A1/en not_active Ceased
- 2016-09-07 SG SG10201913151TA patent/SG10201913151TA/en unknown
- 2016-09-07 JP JP2018512998A patent/JP6959909B2/ja active Active
-
2019
- 2019-11-25 US US16/694,024 patent/US11826384B2/en active Active
-
2021
- 2021-04-27 JP JP2021075261A patent/JP7298103B2/ja active Active
-
2023
- 2023-05-26 JP JP2023086702A patent/JP2023109956A/ja active Pending
- 2023-10-17 US US18/488,400 patent/US20240091256A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN108243607A (zh) | 2018-07-03 |
| US11826384B2 (en) | 2023-11-28 |
| AU2016318773B2 (en) | 2024-08-01 |
| EP3347026A4 (en) | 2019-05-08 |
| US20240091256A1 (en) | 2024-03-21 |
| US10525082B2 (en) | 2020-01-07 |
| JP7298103B2 (ja) | 2023-06-27 |
| JP2021118723A (ja) | 2021-08-12 |
| US20200155597A1 (en) | 2020-05-21 |
| SG10201913151TA (en) | 2020-03-30 |
| WO2017044487A1 (en) | 2017-03-16 |
| JP6959909B2 (ja) | 2021-11-05 |
| JP2018528774A (ja) | 2018-10-04 |
| HK1257460A1 (zh) | 2019-10-18 |
| JP2023109956A (ja) | 2023-08-08 |
| US20170087185A1 (en) | 2017-03-30 |
| AU2016318773A1 (en) | 2018-04-12 |
| EP3347026A1 (en) | 2018-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240091256A1 (en) | Genetic engineering of macrophages for immunotherapy | |
| Moyes et al. | Genetically engineered macrophages: a potential platform for cancer immunotherapy | |
| JP7412885B2 (ja) | 細胞の異なる亜型の活性を選択的にモジュレートするための方法 | |
| IL280215B (en) | Cancer treatment using a chimeric receptor antigen (car) against cd19 | |
| JP2022545541A (ja) | 組み合わせがん免疫療法 | |
| CN116745427A (zh) | 用于递送多种多核苷酸的载体系统及其用途 | |
| EP4243839A1 (en) | Genetically modified natural killer cells and methods of use thereof | |
| US20210077554A1 (en) | Methods of Neoplasm Treatment Utilizing Complementary Oncolytic Viruses and CAR T-Cells | |
| Kim et al. | Reprogramming of IL-12 secretion in the PDCD1 locus improves the anti-tumor activity of NY-ESO-1 TCR-T cells | |
| US20220064672A1 (en) | Engineered oncolytic viruses expressing pd-l1 inhibitors and uses thereof | |
| KR20230074713A (ko) | Socs1에 결함이 있는 면역 세포 | |
| CN119998322A (zh) | 基因编辑靶基因以增强自然杀伤细胞功能 | |
| AU2022335705A1 (en) | Methods for generating primary immune cells | |
| WO2022210487A1 (ja) | 抗原に特異的な受容体を発現する免疫細胞の製造方法 | |
| US20240316106A1 (en) | Methods for generating primary immune cells | |
| US20240342280A1 (en) | Optimizing t cell differentiation state with micrornas | |
| Xia | Cancer Immunogene Therapy Using Viral Vectors Encoding Cytokines and Chimeric Antigen Receptors | |
| WO2023070041A1 (en) | Enhanced immune cell therapy | |
| WO2024226918A1 (en) | Using reprogrammed, personalized cancer stem cells as a triple-killer cancer treatment | |
| EA042086B1 (ru) | Способы селективной модуляции активности отдельных подтипов клеток | |
| NZ787394A (en) | Methods for selectively modulating the activity of distinct subtypes of cells | |
| NZ787396A (en) | Methods for selectively modulating the activity of distinct subtypes of cells | |
| NZ787402A (en) | Methods for selectively modulating the activity of distinct subtypes of cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210902 |
|
| EEER | Examination request |
Effective date: 20210902 |
|
| EEER | Examination request |
Effective date: 20210902 |
|
| EEER | Examination request |
Effective date: 20210902 |
|
| EEER | Examination request |
Effective date: 20210902 |
|
| EEER | Examination request |
Effective date: 20210902 |